What test results and factors should be considered when choosing an acute myeloid leukemia (AML) treatment? Expert Dr. Ellen Ritchie explains how test results impact AML prognosis and treatment – and other factors that come into play when determining a treatment approach. Dr. Ellen K. Ritchie is assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College of Cornell University and the New York Presbyterian Hospital. More about Dr. Ritchie, here: [ Ссылка ].
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect
Factors to Consider When Choosing an AML Treatment
Теги
Dr. Ellen RitchieWeill Cornell MedicineAcute Myeloid LeukemiaAMLAML treatmenttherapy genetic testingacute leukemia treatmentCytogeneticsfluorescence in situ hybridizationMolecular Testingnext generation sequencingFLT3 InhibitorsgilteritinibxospatasorafenibnexavarIDH InhibitorsenasidenibidhifaivosidenibtibsovoBCL-2 inhibitorsvenclextavenetoclaxMLL RearrangementFLT3IDH1IDH2NPM1MLLASXL1RUNX1FDAFDA approvalhematologygene mutations